You just read:

Novartis' Gilenya, Sanofi's Aubagio, Biogen's Tysabri and Tecfidera Capture the Majority of Recent Switches in the European Multiple Sclerosis Market Boosted by Frequent Neurologist Endorsement

News provided by

Spherix Global Insights

Aug 13, 2019, 04:53 ET